Santaris Pharma A/S resumes full ownership of cancer programs licensed to Enzon Pharmaceutical Inc.

  Santaris Pharma A/S resumes full ownership of cancer programs licensed to
                          Enzon Pharmaceutical Inc.

PR Newswire

HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013

HOERSHOLM, Denmark and SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Santaris
Pharma A/S, a clinical-stage biopharmaceutical company focused on the
discovery and development of RNA-targeted therapies, today announced that the
Company and its long term partner, Enzon Pharmaceutical Inc., have agreed that
all rights, data, products and intellectual properties relating to Enzon
Pharmaceutical Inc.'s LNA programs, developed under a license from Santaris
Pharma A/S, will revert to Santaris Pharma A/S. Further Enzon Pharmaceutical
Inc. will transfer an undisclosed amount to Santaris Pharma A/S.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO)

Henrik Stage, President & CEO at Santaris Pharma A/S stated: "We have been
very pleased with the collaboration and are excited to resume full ownership
of these important cancer programs, of which several are under clinical
development." 

About Locked Nucleic Acid (LNA) Drug Platform
The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma
A/S combines the company's proprietary LNA chemistry with its highly
specialized and targeted drug development capabilities to rapidly deliver
LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a
range of diseases including cardiometabolic disorders, infectious and
inflammatory diseases, cancer and rare genetic disorders. LNA is also
sometimes referred to as BNA (Bicyclic or Bridged Nucleic Acid). LNA-based
drugs are a promising new class of therapeutics that enable scientists to
develop drugs that work through previously inaccessible clinical pathways. The
LNA Drug Platform overcomes the limitations of earlier antisense and siRNA
technologies to deliver potent,single-stranded, LNA-based drug candidates
across a multitude of disease states. The unique combination of small size and
very high affinity allows this new class of drugs candidates to potently and
specifically inhibit RNA targets in many different tissues without the need
for complex delivery vehicles. The most important features of LNA-based drugs
include excellent specificity providing optimal targeting; increased affinity
to targets providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S
Santaris Pharma A/S is a privately held, clinical-stage biopharmaceutical
company focused on the discovery and development of RNA-targeted therapies.
The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine
developed by Santaris Pharma A/S combine the company's proprietary LNA
chemistry with its highly specialized and targeted drug development
capabilities to rapidly deliver potent single-stranded LNA-based drug
candidates across a multitude of disease states. The company's research and
development activities focus on infectious diseases and cardiometabolic
disorders, while partnerships with major pharmaceutical companies address a
range of therapeutic areas including cancer, cardiovascular disease,
infectious and inflammatory diseases, and rare genetic disorders. The company
has strategic partnerships with RaNA Therapeutics, Bristol-Myers Squibb,
miRagen Therapeutics, Shire plc., Pfizer, GlaxoSmithKline, and Enzon
Pharmaceuticals. As part of its broad patent estate, the company holds
exclusive worldwide rights to manufacture and sell products that comprise LNA
as active ingredient for studies performed with a view to obtaining marketing
approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark
with operations in the United States. Please visit www.santaris.com for more
information.

Santaris Pharma A/S^® is a registered trademark of Santaris Pharma A/S.
Santaris^TM , Santaris Pharma^TM , Cureon^TM and LNA-antimiR™ are trademarks
of Santaris Pharma A/S.

About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company that had been dedicated
to the research and development of innovative therapeutics for patients with
high unmet medical needs. Enzon receives royalty revenues on seven marketed
products that utilize its proprietary Customized PEGylation Linker Technology
(Customized Linker Technology®) platform, namely PegIntron®, Sylatron®,
Macugen®, CIMZIA®, OMONTYS®, Oncaspar and Adagen.

Further information about Enzon can be found on the Company's website at
www.enzon.com.

SOURCE Santaris Pharma A/S

Website: http://www.santaris.com
Contact: Henrik Stage, President & CEO, Cell: +45 40260900, Company phone: +45
45 17 98 88, e-mail: hs@santaris.com, www.santaris.com
 
Press spacebar to pause and continue. Press esc to stop.